A new study from IHME contributors on “Inequalities in life expectancy among US counties, 1980 to 2014” has provoked widespread attention and discussion from media organizations, decision-makers, and the public.While life expectancy has increased for the US as a whole, the inequality among counties and regions was far more dramatic than most expected, with differences of as much as 20 years between the counties with the highest and lowest life expectancies.
In Ethiopia the Global Burden of Disease (GBD) study is being used to support the Ministry of Health’s drive to strengthen evidence-based decision-making, in collaboration with key partners.
Those who influence decisions on development assistance for health are facing a “very uncertain, dramatic moment that is unprecedented,” said Stephen Morrison, Senior Vice President and Director of the Global Health Policy Center at the Center for Strategic and International Studies, speaking April 20 at a policy briefing in Washington, DC. The discussion focused on two newly published papers on financing global health by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.
In Sweden, the Department of Public Health Sciences, Karolinska Institute, and the Center for Epidemiology and Community Medicine (CES) collaborated with IHME to develop estimates for the burden of disease in Stockholm County. These are now a key feature of the county’s Public Health Guide, which serves as a valuable reference for Stockholm’s government and civil society as they work to promote health and prevent disease.
Earlier this month, the GBD 2015 Tobacco Collaborators published a new report on smoking prevalence and the global burden of tobacco use in The Lancet.
Some people smoke and live seemingly long lives. Yet tobacco is unquestionably harmful. How do we reconcile the two? A recent post published on the Brookings Institute’s Future Development blog used Global Burden of Disease data to educate readers about “selection bias,” or the human tendency to focus on anecdotal accounts that defy the trends while ignoring the much larger body of evidence that supports them.
The World Health Organization Regional Office for Europe (WHO/Europe) and its members view burden of disease data as an essential component of population health monitoring, and an important indicator for policy change. As a result, these bodies have joined forces with the Institute for Health Metrics and Evaluation (IHME) to carry out detailed disease burden analyses in the region.
During his recent visit to IHME’s offices, we sat down with Dr. Yohannes Kinfu, member of the Global Burden of Disease (GBD) study’s Scientific Council and the person who came up with the idea that led to the creation of the Socio-demographic Index (SDI), a new metric for measuring development. SDI allows people to compare countries’ health outcomes and the performance of health systems, and better understand what tomorrow’s health landscape will look like.
On March 21, 2017, the Center for Strategic and International Studies’ (CSIS) Task Force on Women’s and Family Health outlined a road map for the Trump administration to improve the lives of adolescent girls and young women in 13 low-income countries, using IHME’s research to make their case.
The Ministry of Health of Ghana is using burden of disease data to identify the biggest health problems in the country and guide health planning.
In Norway, the government is helping improve the science behind the Global Burden of Disease (GBD) study and incorporating it into their decision-making. The March 2016 launch of the report on GBD findings in Norway has received extensive coverage by the Norwegian media.
On February 8, the University of Washington Department of Global Health (UWDGH) convened renowned thought leaders from around the world to explore the evolving field of global health through presentations, panel discussions, and audience Q&A’s. Health metrics sciences play an important role in driving decisions and programs aimed at improving the health of the world’s populations, and the significance of good evidence and IHME’s impact was made apparent by many speakers during the event.
In the historic city of Porto, famous for being a critical center of trade, health organizations from across Portugal have come together to celebrate a new partnership between Portugal and the Institute for Health Metrics and Evaluation to advance the work of the Global Burden of Disease enterprise and provide insight to guide policymaking in the country.
The paper, “US spending on personal health care and public health, 1996–2013,” published recently in JAMA, found that just 20 conditions make up more than half of all spending on health care in the United States. The paper’s findings have elicited a variety of recommendations from health care experts from the private sector and an architect of the Affordable Care Act.
Data collected by IHME during its evaluation of the Salud Mesoamerica Initiative (SMI) is driving improvements in the health systems that serve some of the Americas’ poorest people.
On December 13, 2016, President Obama signed the 21st Century Cures Act into law. Intending to “accelerate the discovery, development, and delivery of 21st century cures,” the act emphasizes using burden of disease data to prioritize areas of research and innovation.
Researchers and clean air advocates in India have used GDB data to highlight the health impacts of air pollution, and to guide the development of a pioneering new framework to address this major risk factor.
Facing the dual challenge of aging societies and the rise of non-communicable diseases, health experts in countries like Italy are using burden of disease data to help guide policymaking.
The deadline for nominations for the 2017 Roux Prize – January 31, 2017 – is approaching quickly. To provide inspiration, we are revisiting the story of last year’s winner, Dr. John Q. Wong. Dr. Wong used burden of disease data to help the country’s government insurance program expand coverage to 15 million people most in need and reduce their out-of-pocket costs for health care.
Results from IHME’s Global Burden of Disease study have consistently ranked air pollution as a leading risk factor for death and disability, particularly for women and children. Using these findings, US senator Susan Collins introduced a bill that calls for more US involvement in the Global Alliance for Clean Cookstoves, a public-private partnership supported by the UN Foundation, to help achieve its 2020 goals.
Diabetes is an increasingly important health threat in many African countries, and is fast becoming a leading cause of non-communicable-disease-related death and disability on the continent. A new report by IHME, launched in Nairobi at the Pan African World Diabetes Day Forum, is helping the Kenyan Ministry of Health frame its strategy for tackling the disease.
When it comes to how Americans die, not all counties are created equal. IHME’s latest findings reveal a 15-year difference between counties with the lowest and highest life expectancies for American women in 2013 – 71 years in McDowell County, West Virginia, to 86 years in Marin County, California.
What are essential medicines and who should pay for them, especially in lower-income countries? Those questions and others were studied by The Lancet’s Commission on Essential Medicines Policies and explored in a series of articles published recently in the London-based medical journal.
While decision-makers, researchers, and clinicians around the globe regularly use Global Burden of Disease (GBD) estimates to inform their work and set policy, educators are also finding value in incorporating this research and IHME resources into their curricula.
Over the past few years, the Global Burden of Disease (GBD) study has grown a network of expert collaborators with an array of experience, competencies, and disciplines, and it is this diversity of perspective that makes GBD the most comprehensive view of global health burden in the world. One collaborator, Dr. Jayaraman, discussed her unique vantage point as a clinician in October during the GBD 2015 launch event, and we had the opportunity to learn more about Dr. Jayaraman’s experiences after the event.